Cancer care is growing increasingly complicated, with projections estimating more than 35 million new cases by 2050 across over 100 cancer types. Clinicians face the dual challenge of working within fragmented systems filled with unstructured data and making timely, personalised decisions for each patient.
Helsinki-based Gosta Labs was created to meet this challenge head-on by building an AI operating system tailored to complex medical specialities such as oncology. Its AI assistant streamlines the process by automating clinical documentation, structuring patient data as it is gathered, visualising the patient journey, and linking care decisions to international treatment guidelines.
Today, Gosta Labs raised €7.5 million in seed funding, led by Voima Ventures, with support from COR Group, the Aho family, Reaktor, and several angel investors, following a €1.7 million pre-seed round.
Gosta Labs co-founders, Lauri Sippola and Henri Viertolahti, told TFN, “Gosta Labs has raised a total of €10 million to date, after completing the recent €7.5 million seed round in November 2025. We are not disclosing our valuation at this time. “
Scaling an AI assistant for cancer care
Founded in 2023 by Lauri Sippola and Henri Viertolahti, experienced entrepreneurs behind the health-tech company Kaiku Health (acquired by Elekta in 2020), Gosta Labs was born out of a desire to relieve care teams of the burdensome documentation that drains their time.
“We started Gosta Labs to bring AI to support extremely complex medical specialities like oncology, to give care teams back time and headspace for their patients by taking on the documentation work that drains their day,” said Sippola.
The company is developing an AI operating system for complex medical specialities, like oncology, enabling more efficient, precise, and personalised care across the entire patient journey.
The system summarises and visualises patient journeys, automates clinical documentation, and captures structured clinical data relevant to patient care. It also improves the quality of care by assessing key clinical parameters for each treatment pathway and automatically linking decisions to international guidelines.
The founders elaborated to TFN, “Gosta has trained and implemented proprietary task-specific language models for oncology tasks. We have been working together with the LUMI supercomputer in Finland since early 2024.”
While companies such as PathAI and RISA Labs also offer oncology AI tools, Gosta Labs distinguishes itself through its deep clinical domain expertise, rigorous medical device-grade development, strong European infrastructure, and proven ability to slash documentation times by more than two-thirds, as demonstrated at the 2025 ESMO conference.
Gosta Labs’ AI operating system is already in use with leading healthcare providers in Finland, Switzerland, the Baltics, and Australia.
What about diversity?
When we asked about diversity, founders confirmed, “After recent hiring, the gender ratio of our leadership team is 40% female and 60% male. Our team represents four different nationalities across Europe.”
What’s next?
With new seed funding secured, Gosta Labs is set to expand its reach by partnering with leading cancer centres across Europe, Australia, and beyond. The company plans to strengthen its AI models and advance medical device certification, ensuring its platform delivers ever more accurate, consistent, and safe patient care.
Jussi Sainiemi, Partner at Voima Ventures, notes, “There’s a lot of hype around AI, but Gosta delivers the value it promises, and customers love the product.”
